Sandy Spring Bank’s Ginkgo Bioworks DNA Stock Holding History

Sandy Spring Bank’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50	Closed	-$408	–	1247
2024 Q3	$408	Buy	+50	New	+$501	﹤0.01%	1127

Other funds holding DNA

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sandy Spring Bank's DNA Position: Q4 2024 in Review

Sandy Spring Bank sold out of Ginkgo Bioworks (DNA) in Q4 2024, closing a stake of 50 shares — an estimated $408 sold.

Sandy Spring Bank first reported a position in DNA in Q3 2024 and held it in 1 quarter. The position peaked at $408 in Q3 2024. 165 funds tracked by Wall St. Rank hold DNA as of Q4 2024.

Sandy Spring Bank reported no remaining Ginkgo Bioworks position as of Q4 2024 after selling out during the quarter.
Sandy Spring Bank sold 50 Ginkgo Bioworks shares in Q4 2024, an estimated $408.
Sandy Spring Bank first reported a position in Ginkgo Bioworks in Q3 2024 and held it in 1 quarter.
Sandy Spring Bank's Ginkgo Bioworks position peaked at $408 in Q3 2024.
165 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2024.

Based on Sandy Spring Bank's 13F filing for Q4 2024, filed 11 Feb 2025.